| abstract |
The present invention relates to EPAS1-related diseases such as cancer, metastasis, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal cancer, gastric cancer, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma , Neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, renal clear cell cancer (as well as metastasis of this cancer and other cancers), gingivitis, psoriasis, Kaposi sarcoma Provision of treatments for related herpesviruses, preemclampsia, inflammation, chronic inflammation, angiogenic diseases, and rheumatoid arthritis. A composition comprising an RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand has at least 0, 1, 2 or 3 nucleotides different from the antisense strand of the RNAi agent against EPAS1. A composition is used which contains 15 consecutive nucleotides. [Selected figure] Figure 1 |